Trading volume for Aclaris Therapts Cmn was 955K in the last trading session. Shares saw a steep increase in trading volume of 259.69% over the normal average daily volume.
Traders are a little more bearish on shares of the company lately as evidenced by the motion in short interest. The company realized a rise in short interest of 1.29% between September 29, 2017 and October 13, 2017. Short interest increased 39,673 over that period. With short interest at 3,119,623 and short average daily volume at 341,668, days to cover is 9.0 and the short interest percentage is 0.10% as of October 13.
These firms have modified their investment in ACRS. Tiaa Cref Investment Management LLC added to its holdings by buying 15,207 shares an increase of 7.1%. Tiaa Cref Investment Management LLC owns 230,148 shares valued at $5,940,000. The value of the position overall is up by 1.9%. Foresite Capital Management Iii, LLC bolstered its stake by buying 122,950 shares an increase of 87.8% in the quarter. Foresite Capital Management Iii, LLC claims 262,950 shares with a value of $6,787,000. The total value of its holdings increased 62.6%.
Loomis Sayles & Co L P expanded its ownership by buying 73,259 shares an increase of 15.3% from 06/30/2017 to 09/30/2017. Loomis Sayles & Co L P now holds 550,876 shares worth $14,218,000. The total value of its holdings increased 9.8%. Westfield Capital Management Co Lp divested its position by selling 157,310 shares a decrease of 12.6% as of 09/30/2017. Westfield Capital Management Co Lp now controls 1,091,944 shares valued at $28,183,000. The total value of its holdings decreased 16.8%.
November 7 investment analysts at Cantor Fitzgerald held the stock rating at “Buy” with a current price target of $50.00. On October 4 analysts at Cantor Fitzgerald released guidance on ACRS and giving a rating of “Buy” and projecting a price target of $50.00.
On September 26 Cantor Fitzgerald held the company rating at “Buy” targeting a price of $50.00. On September 18 Cantor Fitzgerald kept the company rating at “Buy” projecting a price of $50.00.
September 8 investment analysts at JMP Securities maintained a company rating of “Outperform” projecting a price of $39.00. On August 9, 2017 Cantor Fitzgerald updated coverage of ACRS with a rating of “Buy” and setting a price target of $50.00.
The company is up from yesterday’s close of 22.33. Aclaris Therapts Cmn currently has a P/E ratio of N/A and the market cap of the company is 672.22M. As of the latest earnings report the EPS was $-2.16 with 30.83M shares now outstanding.
Aclaris Therapeutics, Inc., launched on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications..